Cost-effectiveness of Merck’s potential hypertension drug will hinge on long-term data, ICER says

ICER has pub­lished a draft re­port on the po­ten­tial cost-ef­fec­tive­ness of Mer­ck’s so­tater­cept, a po­ten­tial first-in-class fu­sion pro­tein un­der US re­view as an add-on ther­a­py for pul­monary ar­te­r­i­al hy­per­ten­sion (PAH).

PAH has di­rect med­ical costs of $100,000 per per­son per year, ac­cord­ing to ICER. The con­di­tion af­fects be­tween 50,000 and 100,000 peo­ple in the US, and it is more com­mon in women than in men.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.